# LAI-PrEP Bridge Decision Support Tool
## License

**Pharma-Restricted Open Healthcare License v1.0**

Copyright ¬© 2024-2025 Adrian C. Demidont and Kandis Backus

---

## Quick Summary

| User Type | Access Level | Requirements |
|-----------|--------------|--------------|
| üè• Healthcare Providers | **FREE - Unrestricted** | Attribution only |
| üî¨ Researchers & Academics | **FREE - Unrestricted** | Attribution only |
| üéóÔ∏è Non-Profit Organizations | **FREE - Unrestricted** | Attribution only |
| üèõÔ∏è Government Agencies | **FREE - Unrestricted** | Attribution only |
| üíä Pharmaceutical Companies | **RESTRICTED** | Written permission required* |
| üß¨ Biotechnology Companies | **RESTRICTED** | Written permission required* |

\* **Exception:** May use for direct patient care with notification (see Patient Care Use below)

---

## For Healthcare Providers, Researchers, and Non-Profits

### ‚úÖ You Are Authorized To:

- Use the tool **without restriction** for patient care
- Use for research and academic purposes
- Modify and create derivative works
- Distribute the tool and derivatives
- Integrate into electronic health records
- Publish research findings
- Use for quality improvement
- Use for public health program planning
- Use for education and training

### üìã Your Only Obligation:

Include this attribution:

```
This work uses the LAI-PrEP Bridge Decision Support Tool developed by
Adrian C. Demidont, DO and Kandis Backus, PharmD.
Copyright ¬© 2024-2025. Available at: https://github.com/Nyx-Dynamics/lai-prep-bridge-decision-tool

Citation: Demidont, A.C.; Backus, K.V. Computational Validation of Clinical
Decision Support Algorithm for Long-Acting Injectable PrEP Bridge Period
Navigation at UNAIDS Global Target Scale. Viruses 2025.
```

**No permission needed. No fees. No restrictions.**

---

## For Pharmaceutical & Biotechnology Companies

### ‚ö†Ô∏è Commercial Use Requires Permission

Pharmaceutical entities (defined below) **MUST obtain written permission** for:
- Internal business use (strategy, market analysis)
- Product development or enhancement
- Marketing or promotional activities
- Competitive intelligence
- Clinical trials sponsored by pharmaceutical companies
- Integration into proprietary software platforms
- Any use supporting commercial pharmaceutical activities

### ‚úÖ Patient Care Use Exception

Pharmaceutical companies **MAY use without permission** if:

1. **Limited to direct patient care** by employed/contracted clinicians
2. **Not used for** marketing, sales support, or competitive analysis
3. **Notify us** within 30 days of implementation:
   - Email: acdemidont@nyxdynamics.org
   - Include: Scope of use, number of sites, implementation date
4. **Provide annual reporting**:
   - Number of patients assessed
   - Clinical outcomes (de-identified)
   - Any modifications made

**No fees for patient care use. Just notification and outcome reporting.**

### üìß How to Request Commercial Use Permission

1. Email: **acdemidont@nyxdynamics.org**
2. Include:
   - Detailed description of intended use
   - Expected scale of implementation
   - Products/services that will benefit
   - Proposed contribution to implementation science
3. We commit to:
   - Respond within **30 business days**
   - Consider requests fairly and in good faith
   - Prioritize public health impact
   - Be receptive to partnerships advancing implementation science

---

## Definitions

### "Pharmaceutical Entity" Includes:

- Manufacturers of HIV prevention/treatment medications
- Manufacturers of long-acting injectable formulations (cabotegravir, lenacapavir, etc.)
- Biotechnology companies developing HIV products
- Medical device manufacturers (drug delivery systems for injectables)
- Contract research organizations (CROs) working for pharma/biotech
- Parent companies, subsidiaries, or affiliates of above

### "Commercial Use" by Pharmaceutical Entity Means:

- Internal business operations (sales, strategy, market analysis)
- Product development, enhancement, or positioning
- Marketing, promotional, or sales support materials
- Competitive intelligence or market research
- Clinical trial infrastructure for pharma-sponsored trials
- Any use directly/indirectly supporting commercial pharmaceutical activities

### "Patient Care Use" Means:

- Direct clinical assessment of individual patients
- Selection of appropriate interventions for patients
- Improving bridge period navigation outcomes
- Providing better patient care

---

## Warranty Disclaimer

THE WORK IS PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NONINFRINGEMENT.

IN NO EVENT SHALL THE AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES, OR OTHER LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT, OR OTHERWISE, ARISING FROM, OUT OF, OR IN CONNECTION WITH THE WORK OR THE USE OR OTHER DEALINGS IN THE WORK.

---

## Clinical Use Disclaimer

This clinical decision support tool is intended to **ASSIST** healthcare providers, not replace clinical judgment. All clinical decisions remain the sole responsibility of treating healthcare providers.

This tool has been **computationally validated** but requires **prospective clinical validation** before widespread deployment.

---

## Preservation of Terms

Any redistribution or derivative work must:
- Preserve this license in its entirety
- Maintain all restrictions on Pharmaceutical Entities
- Include copyright notice and attribution requirements
- Not misrepresent the work as endorsed by original authors

---

## Frequently Asked Questions

### Q: I'm a clinician working for a pharma company. Can I use this?

**A:** Yes! Under the Patient Care Use exception. Just notify us within 30 days and provide annual outcome reports. No fees.

### Q: I'm a researcher at a university receiving pharma funding. Can I use this?

**A:** Yes! Academic freedom is fully protected. Researchers have unrestricted access regardless of funding source.

### Q: Can a hospital that receives pharma grant money use this?

**A:** Yes! Healthcare providers have full unrestricted access regardless of funding sources. The restriction applies to pharmaceutical companies' own internal use, not to organizations they support.

### Q: What if my clinic has a pharma company on our advisory board?

**A:** You still have full unrestricted access. The restriction targets pharma companies' commercial operations, not clinical care settings.

### Q: Can I publish research using this tool?

**A:** Yes! Publish freely. Just cite appropriately. No permission needed.

### Q: What if I'm unsure whether I need permission?

**A:** Email us: acdemidont@nyxdynamics.org. We'll respond within 5 business days with clarification. We're friendly and want to help!

### Q: Will you grant permission to pharmaceutical companies?

**A:** We evaluate requests fairly, prioritizing public health impact. We're open to partnerships involving data sharing, validation studies, and health equity initiatives. We will not unreasonably withhold permission for uses that advance implementation science and patient care.

### Q: Why this license structure?

**A:** To maximize patient access (free for all healthcare) while ensuring pharmaceutical companies‚Äîwho profit substantially from HIV prevention products this tool helps implement‚Äîcontribute fairly when using academic work for commercial purposes. It balances open science with fair value exchange.

---

## Rationale

This license embodies our values:

1. **Open Science** ‚Üí All code and data publicly available
2. **Maximum Health Impact** ‚Üí No barriers for healthcare providers
3. **Health Equity** ‚Üí Free for safety-net and under-resourced providers
4. **Fair Value Exchange** ‚Üí Pharma contributes when deriving commercial value
5. **Academic Freedom** ‚Üí Unrestricted research use
6. **Collaborative Partnerships** ‚Üí Open to working with all stakeholders

---

## Contact Information

**For questions, permission requests, or compliance guidance:**

**Adrian C. Demidont, DO**  
Email: acdemidont@nyxdynamics.org  
Organization: Nyx Dynamics, LLC  
Location: Fairfield, CT, USA

We commit to responding promptly and working collaboratively with all stakeholders to maximize public health impact.

---

## Citation

### Software:
```
Demidont, A.C.; Backus, K.V. LAI-PrEP Bridge Period Decision Support Tool.
Version 2.1.0. 2025. https://github.com/Nyx-Dynamics/lai-prep-bridge-decision-tool
DOI: 10.5281/zenodo.17429833
```

### Manuscript:
```
Demidont, A.C.; Backus, K.V. Computational Validation of Clinical Decision
Support Algorithm for Long-Acting Injectable PrEP Bridge Period Navigation
at UNAIDS Global Target Scale. Viruses 2025, [volume], [article number].
```

### BibTeX:
```bibtex
@software{demidont2025laiprep,
  author = {Demidont, Adrian C. and Backus, Kandis V.},
  title = {LAI-PrEP Bridge Period Decision Support Tool},
  version = {2.1.0},
  year = {2025},
  url = {https://github.com/Nyx-Dynamics/lai-prep-bridge-decision-tool},
  note = {Pharma-Restricted Open Healthcare License v1.0}
}
```

---

## Full License Text

For the complete legal text, definitions, detailed terms, and comprehensive FAQ, see:
**[PHARMA_RESTRICTED_LICENSE.md](PHARMA_RESTRICTED_LICENSE.md)**

---

**License Version:** 1.0  
**Effective Date:** January 2025  
**SPDX-License-Identifier:** LicenseRef-Pharma-Restricted-Open-Healthcare-1.0  
**Last Updated:** January 2025
